Ricovr Healthcare secures NIH grant to develop XALIVA®, an
innovative cannabis screening device, aiming to revolutionize drug
testing with accurate, point-of-care THC detection.
PRINCETON, N.J., July 24,
2024 /PRNewswire-PRWeb/ -- Ricovr Healthcare is proud
to announce that it has been awarded a competitive Small Business
Innovation Research grant from the National Institute on Drug Abuse
(NIDA) at the National Institutes of Health (NIH) for the
development of its groundbreaking cannabis testing platform,
XALIVA®. This innovative device aims to revolutionize drug
screening and enhance public safety by providing accurate THC
quantification in saliva using its automated point-of-care
platform.
The NIH grant will support Ricovr in creating an effective,
scalable, and accurate device that aims to address the growing need
for reliable drug screening solutions. XALIVA® strives to be a
game-changer in the industry, offering precise and immediate
results for cannabis detection.
Dr. Joseph Seimetz, Director of
Research and Development at Ricovr Healthcare, will serve as the
Principal Investigator for this project. Dr. Seimetz remarked, "We
are thrilled to receive this NIH SBIR grant, which will enable us
to advance our technology with the goal to bring a much-needed
solution to the market. Our aim is to provide an easy-to-use,
accurate, and reliable device that enhances public safety and
addresses the challenges of on-site drug testing."
Dr. Himanshu Bhatia, CEO and
founder of Ricovr Healthcare, will serve as the Co-Investigator.
Dr. Bhatia commented, "We are extremely proud of securing this
grant. This further validates our technology and underscores the
importance of our mission. With the support of the NIH, we are
confident that XALIVA® can set a new standard in drug screening and
help ensure a safer environment for all."
Ricovr Healthcare's grant award from the NIH will accelerate
development of the XALIVA® platform and is a significant milestone
in the company's efforts to advance point-of-care testing across
the healthcare technology sector. As the demand for a reliable and
scalable THC testing solution increases, the market potential for
XALIVA® expands, positioning Ricovr at the forefront of this
critical industry.
Research reported in this press release was supported by the
National Institute on Drug Abuse of the National Institutes of
Health under award number 1R43DA059318. The content is solely the
responsibility of the authors and does not necessarily represent
the official views of the National Institutes of Health.
For more information about Ricovr Healthcare and XALIVA®, please
visit https://www.ricovr.com/ or contact: info@ricovr.com
About Ricovr Healthcare:
Ricovr Healthcare is a leading innovator in point-of-care
diagnostics, committed to enhancing public health and safety
through its advanced optical detection technology. The company's
flagship product, XALIVA® THC, represents the next generation of
cannabis testing, providing accurate and immediate results for THC
quantification in saliva. The Company's product pipeline includes
rapid point-of-care tests for THC, drug screening, reproductive
health, and infectious diseases. The Company boasts an excellent
management team of scientists and engineers, a distinguished
advisory board, and excellent academic and industry partners around
the globe all committed to improving diagnostics.
Media Contact
Rachel Harris, Pulse Media,
949-749-5349, info@pulsemediapr.com
View original content to download
multimedia:https://www.prweb.com/releases/ricovr-healthcare-awarded-nih-grant-to-advance-development-of-point-of-care-cannabis-screening-platform-302204943.html
SOURCE Ricovr Healthcare